Wegovy and Ozempic are the same drug. Both contain semaglutide, made by the same manufacturer, and work through identical biological pathways. The real difference is what they’re approved for and how much you take: Ozempic is prescribed for type 2 diabetes, while Wegovy is prescribed for weight loss. Because Wegovy delivers a higher dose, it produces more weight loss, but Ozempic remains the better-studied option for blood sugar control.
Same Drug, Different Doses
Semaglutide is a synthetic version of a gut hormone called GLP-1 that your small intestine naturally produces after eating. It works in two ways: it signals your pancreas to release more insulin when blood sugar rises, and it slows how quickly food moves through your digestive tract. That slower emptying keeps you feeling full longer after meals, making it easier to eat less without white-knuckling through hunger. Semaglutide also acts on appetite centers in the brain, dialing down the food noise that drives overeating.
The critical distinction is dosage. Ozempic tops out at 2 mg per week, while Wegovy’s standard maintenance dose is 2.4 mg per week. For patients who need additional weight reduction, Wegovy can now be prescribed at doses up to 7.2 mg weekly. Both are once-weekly injections, and both follow a gradual dose-escalation schedule over several months to minimize nausea and other gastrointestinal side effects.
Weight Loss: Wegovy Has the Edge
If your primary goal is losing weight, Wegovy is the stronger option simply because of the higher dose. In the STEP 10 clinical trial, participants taking the 2.4 mg dose lost an average of 13.9% of their body weight over one year, compared to 2.7% in the placebo group. That translates to roughly 30 to 35 pounds for someone starting at 250 pounds.
Ozempic does cause significant weight loss too, which is why many doctors prescribe it off-label for that purpose. But its lower maximum dose means the results are typically more modest. Most clinical data for Ozempic’s weight effects come from diabetes trials where weight loss was a secondary outcome, not the primary goal. If you’re being prescribed semaglutide specifically for weight management, Wegovy is the version designed and dosed for that job.
Blood Sugar Control: Ozempic’s Strength
For people with type 2 diabetes, Ozempic is the FDA-approved choice. In real-world data from over 1,200 patients who stayed on treatment, the 1.0 mg weekly dose reduced HbA1c (a three-month average of blood sugar levels) by 1.4 percentage points. That’s a substantial improvement, often enough to move someone from poorly controlled diabetes into a healthier range.
Wegovy isn’t approved for diabetes treatment, though semaglutide at any dose will lower blood sugar. The distinction matters for insurance and prescribing: if you have type 2 diabetes, your doctor will typically prescribe Ozempic. If you have obesity or are overweight with a weight-related health condition, Wegovy is the intended prescription. Some people have both conditions, which is where the choice gets more nuanced and depends on which problem your doctor is prioritizing.
Heart Health Benefits
Wegovy holds a unique advantage here. In the large SELECT trial, the 2.4 mg dose reduced the risk of heart attack, stroke, and cardiovascular death by 20% in people with existing heart disease who were overweight or obese but did not have diabetes. Based on those results, the FDA approved Wegovy in March 2024 as the first weight-loss medication specifically indicated to reduce serious cardiovascular events.
Ozempic does not carry this cardiovascular indication. That doesn’t mean the lower dose has zero heart benefits, but the landmark trial data belongs to Wegovy’s higher dose. For someone with both obesity and heart disease, this approval gives Wegovy a clinically meaningful edge that goes beyond the scale.
Insurance Coverage and Cost
Coverage remains one of the biggest practical differences between these two medications, and it often determines which one you actually end up taking. Ozempic, as a diabetes drug, is covered by most insurance plans when you have a type 2 diabetes diagnosis. The path to coverage is relatively straightforward.
Wegovy coverage for weight management is more variable. Most commercial plans that do cover it require a BMI above 30, or a BMI above 27 with at least one weight-related condition like high blood pressure or sleep apnea. Some plans impose even stricter thresholds, and others exclude weight-loss medications entirely. A Tufts Medical Center analysis of major commercial health plans found that requirements varied considerably, with a few plans setting BMI cutoffs higher than what the FDA label specifies.
Without insurance, both medications carry similar list prices in the range of $1,000 to $1,300 per month. The semaglutide shortage that drove many patients to compounding pharmacies for cheaper alternatives has since resolved. The FDA declared the shortage over in February 2025, which means supply for both brand-name products has stabilized.
Which One Is Right for You
The answer depends on what you’re treating. If you have type 2 diabetes and want better blood sugar control with some weight loss as a bonus, Ozempic is the established, well-covered choice. If your primary concern is losing weight, especially if you also have cardiovascular risk factors, Wegovy offers a higher dose, stronger weight-loss data, and a proven heart benefit that no other weight-loss drug currently matches.
Neither is objectively “better” because they’re the same molecule aimed at different problems. The side effect profiles are essentially identical since the active ingredient is identical: nausea, vomiting, diarrhea, and constipation are the most common complaints, particularly during the dose-escalation phase. These typically improve after the first two to three months. Rare but serious risks, including pancreatitis and gallbladder problems, apply equally to both.
One scenario worth knowing about: some people start on Ozempic for diabetes, lose substantial weight, and then want to switch to Wegovy to access the higher dose for continued weight loss. This switch is medically straightforward since it’s the same drug, but navigating the insurance transition can be complicated. Your prescriber’s office can often help with prior authorization paperwork if this applies to you.